Current Pharmaceutical Biotechnology

Zeno Foldes-Papp
Visiting Professor of Medical Biochemistry
HELIOS Clinical Center of Emergency Medicine
Department for Internal Medicine
Alte-Koelner-Strasse 9
D-51688 Koeln-Wipperfuerth


Recent Clinical Experience with Oncolytic Viruses

Author(s): O. G. Donnelly, F. Errington-Mais, R. Prestwich, K. Harrington, H. Pandha, R. Vile and A. A. Melcher

Affiliation: Leeds Institute of Molecular Medicine, St James’s University Hospital, Beckett Street, Leeds, UK, LS9 7TF.

Keywords: Oncolytic virus, adenovirus, measles, reovirus, vaccinia, cancer, replication-competent viruses


There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by significant preclinical advances, have focussed on the safety of using replication-competent viruses. Recently published clinical trials of six oncolytic viruses (adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia) have added to the accumulating data that endorse oncolytic viruses as a safe and well tolerated treatment approach. Conclusive evidence of efficacy remains to be demonstrated, but randomised clinical trials are now underway.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1834 - 1841]
Pages: 8
DOI: 10.2174/138920112800958904